Despite being largely preventable through HPV vaccination and regular screening, cervical cancer continues to claim lives in India, with many women diagnosed at an advanced stage. In this Q&A, Dr Sanket Mehta, Founder, Director and Lead Surgical Oncologist at SSO Cancer Hospitals, discusses the gaps in prevention, HPV vaccine awareness, screening access and what India needs to do to move from treating cervical cancer to preventing it.
1. Despite being largely preventable, why does cervical cancer continue to be a major public health challenge in India?
Dr Sanket Mehta: The contradiction is that we have the tools to prevent a significant proportion of cervical cancer cases, yet we continue to diagnose too many women when the disease is advanced. The problem is not a lack of medical knowledge; it is the distance between medical knowledge and its delivery. Prevention requires more than telling women to get screened. It requires accessible services, informed communities, trained healthcare workers and a system that ensures an abnormal result is followed by diagnosis and treatment. Social stigma, limited health-seeking behaviour and the tendency to put women’s health last compound the problem. We must stop treating cervical cancer as an inevitable risk and start treating its prevention as a healthcare delivery responsibility.
2. India has launched a nationwide HPV vaccination campaign targeting 14-year-old girls. How significant is this step, and what gaps does it address?
Dr Sanket Mehta: This is a huge shift from treating cancer after it happens to preventing it before the disease process even begins. India’s nationwide campaign, launched in February 2026, offers free, voluntary, single-dose HPV vaccination to eligible 14-year-old girls at government health facilities, with parental consent. It tackles a major barrier to access: the vaccine should not be something only families who can afford it privately have a choice about. But a national announcement is only the beginning. Its success will depend on coverage, awareness, vaccine confidence and consistent delivery, particularly in underserved communities. We must also remember that vaccination protects future generations; it does not eliminate the need to screen adult women who may already have been exposed to HPV.
3. There are still misconceptions around HPV vaccination, particularly among parents. What are the most common concerns, and how should they be addressed?
Dr Sanket Mehta: The biggest misconception is that HPV vaccination is about sexual behaviour rather than cancer prevention. Some parents are worried that vaccinating an adolescent girl is inappropriate, may affect fertility or could have long-term consequences. These concerns must be addressed with respect and science, not judgement. HPV is a very common and persistent infection; high-risk types can lead to cervical cancer. The vaccine is most effective if given before exposure to the virus, which is why adolescence is the recommended window. Healthcare professionals need to communicate the evidence, safety monitoring and preventive purpose in the language that families can understand. If the healthcare system isn’t talking clearly, we can’t expect parents to make informed choices. Trust is as important as the availability of vaccines.
4. How important is the age of vaccination? Can women who have crossed adolescence also benefit from HPV vaccination?
Dr Sanket Mehta: Timing is important because the HPV vaccine works best when given before a person is exposed to the virus. This is why public health programmes focus on adolescent girls, why India’s campaign is aimed at 14-year-olds. But passage through adolescence does not render vaccination useless. Some older women may still benefit, depending on their age, previous exposure, vaccine eligibility and individual risk. The decision should be made in consultation with a qualified clinician and in accordance with the approved vaccine indications. One point must remain clear: HPV vaccines prevent new infections; they do not treat an existing HPV infection or cervical disease. Vaccination at any eligible age must never become a reason to postpone cervical screening.
5. Cervical cancer can develop without obvious symptoms in its early stages. Who should undergo screening, at what age, and how frequently?
Dr Sanket Mehta: Waiting for symptoms is one of the biggest mistakes in cervical cancer prevention. Precancerous changes can exist without pain, bleeding or any obvious warning sign. Screening is therefore meant for women who feel perfectly well. Broadly, women should begin screening from the age of 30, with earlier screening for certain higher-risk groups, including women living with HIV. The appropriate test and interval depend on national guidelines, the method available and individual risk. HPV testing, cytology and visual inspection methods may be used in different settings. If a woman is experiencing symptoms such as bleeding after intercourse, unexplained vaginal If bleeding or persistent unusual discharge occurs, she should seek medical evaluation rather than waiting for a routine screening appointment.
6. Despite the availability of screening methods, why are so many women diagnosed at an advanced stage? Is it an issue of awareness, access or social stigma?
Dr Sanket Mehta: It is all three, but there is also a fourth issue: a broken follow-through system. A woman may hear about screening but not know where to access it. She may undergo a test but not receive her result promptly. An abnormal result may then lead to another appointment, travel, expense and uncertainty. Each additional step creates an opportunity for her to drop out of care. Social stigma and embarrassment make matters worse, particularly when women have limited control over healthcare decisions within the family. We must measure the success of screening programmes not by how many tests are conducted, but by how many women with abnormal results complete diagnosis and receive timely treatment. Detection without follow-through is an incomplete intervention.
7. What are the biggest challenges in ensuring timely diagnosis and treatment, particularly for women in rural and underserved communities?
Dr Sanket Mehta: The challenge is not simply bringing a screening camp to a village. It is ensuring that a woman who screens positive has a clear, affordable route to a definitive diagnosis and treatment. Many underserved communities face shortages of trained personnel, diagnostic facilities, pathology services and specialist care. Travel costs, lost wages and family responsibilities can further delay treatment. We need decentralised screening and initial evaluation, supported by reliable referral networks to centres equipped to manage complex cases. Though teleconsultation can help in accessing specialists, it can’t substitute the need for physical examination, quality diagnostics and timely treatment. It is the system that has to take the responsibility to guide the patient through each step and not leave her to organise it herself.
8. What needs to change in India’s healthcare system to move from treating cervical cancer to preventing it through vaccination, screening and early intervention?
Dr Sanket Mehta: We need to stop viewing vaccination, screening and treatment as separate healthcare programmes. They must function as one continuous prevention pathway. Adolescent girls should receive timely HPV vaccination; adult women should have access to appropriate screening; and every abnormal result must trigger a defined process for diagnosis, referral and treatment. Primary healthcare facilities should be equipped to identify risk and initiate screening, while district and specialist centres provide diagnostic and treatment support. We also need robust tracking systems so that women do not disappear between a positive test and the next appointment. Ultimately, cervical cancer elimination will not be achieved by a vaccine alone. It will require a healthcare system that takes responsibility for prevention as seriously as it takes responsibility for treatment.
